. Earth Science News .
EPIDEMICS
Antiviral compound offers full protection from Ebola in nonhuman primates
by Staff Writers
San Diego CA (SPX) Oct 13, 2015


File image.

Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.

Travis Warren, Ph.D., a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), said the work is a result of the continuing collaboration between USAMRIID and Gilead Sciences of Foster City, Calif. Scientists at the Centers for Disease Control and Prevention (CDC) also contributed by performing initial screening of the Gilead Sciences compound library to find molecules with promising antiviral activity.

The initial work identified the precursor to GS-5734, a small-molecule antiviral agent, which led to the effort by Gilead and USAMRIID to further refine, develop and evaluate the compound. Led by USAMRIID Science Director Sina Bavari, Ph.D., the research team used cell culture and animal models to assess the compound's efficacy against several pathogens, including Ebola virus.

In animal studies, treatment initiated on day 3 post-infection with Ebola virus resulted in 100 percent survival of the monkeys. They also exhibited a substantial reduction in viral load and a marked decrease in the physical signs of disease, including internal bleeding and tissue damage.

"The compound, which is a novel nucleotide analog prodrug, works by blocking the viral RNA replication process," said Warren. "If the virus can't make copies of itself, the body's immune system has time to take over and fight off the infection."

In cell culture studies, GS-5734 was active against a broad spectrum of viral pathogens. These included Lassa virus, Middle East Respiratory Syndrome (MERS) virus, Marburg virus, and multiple variants of Ebola virus, including the Makona strain causing the most recent outbreak in West Africa.

"This is the first example of a small molecule--which can be easily prepared and made on a large scale--that shows substantive post-exposure protection against Ebola virus in nonhuman primates," Bavari commented. "In addition to 100 percent survival in treated animals, the profound suppression of viral replication greatly reduced the severe clinical signs of disease."

Taken together, the robust therapeutic efficacy observed in primates and the potential for broad-spectrum antiviral activity suggest that further development of GS-5734 for the treatment of Ebola virus and other viral infections is warranted, Bavari said.

According to Tomas Cihlar, Ph.D., of Gilead Sciences, the company is currently conducting phase I clinical studies of the compound in healthy human volunteers to establish the safety and pharmacokinetic profile.

"We are exploring alternative directions for developing this compound, including potential use of the animal efficacy rule," Cihlar said, referring to a regulatory mechanism under which the U.S. Food and Drug Administration may consider efficacy findings from adequate and well-controlled animal studies of a drug in cases where it is not feasible or ethical to conduct human trials.

Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates with high mortality rates and continues to emerge in new geographic locations, including West Africa, the site of the largest outbreak to date. Over 28,000 confirmed, probable and suspected cases have been reported in Guinea, Liberia and Sierra Leone, with over 11,000 reported deaths, according to the World Health Organization. Although several clinical trials are currently underway, there are no licensed vaccines or therapies against Ebola virus.

Research on Ebola virus is conducted in Biosafety Level 4 (maximum containment) laboratories, where investigators wear positive-pressure "space suits" and breathe filtered air as they work. USAMRIID is the only organization in the Department of Defense with Biosafety Level 4 capabilities, and its research benefits both military personnel and civilians.

"Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor that Provides Complete Therapeutic Protection Against Ebola Virus Disease in Infected Non-human Primates."


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


.


Related Links
US Army Medical Research Institute of Infectious Diseases
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola






Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

Previous Report
EPIDEMICS
Cholera cases in Iraq top 1,200: ministry
Baghdad (AFP) Oct 7, 2015
The number of confirmed cases of cholera in Iraq has risen to 1,201, the health ministry said Wednesday of an outbreak that started along the Euphrates river last month. "There are 1,201 confirmed cases as of October 7, 2015," the health ministry said in a statement, adding that most patients had recovered. It said there had been only one confirmed death from the disease, in Babil provin ... read more


EPIDEMICS
Man survives on ants for six days in remote Australia

New warehouse blast hits Tianjin: China state media

LORELEI Imagines Rapid Automated Language Toolkit

Drama therapy breaks new ground for Iraq's teenage girls

EPIDEMICS
Using optical fiber to generate a two-micron laser

Dielectric film has refractive index close to air

Northrop Grumman upgrading G/ATOR radar system

Raytheon's AESA 360-degree radar moves toward production

EPIDEMICS
Global marine analysis suggests food chain collapse

A balanced diet is good for corals too, study finds

Food chain collapse predicted in world's oceans

Sea level rise will swallow Miami, New Orleans: study

EPIDEMICS
Could 'The Day After Tomorrow' happen?

New study projects that melting of Antarctic ice shelves will intensify

Scientists catch billions of juvenile fish under arctic sea ice

Arctic Militarization 'Moot Point' - NORAD Commander

EPIDEMICS
Trade in invasive plants is blossoming

Colorful caterpillar chemists

Accurate timing of migration prolongs life expectancy in pike

Fertilizing and recycling Si in Vietnamese fields

EPIDEMICS
Volcanic eruptions affect flow of world's major rivers

Simulating path of 'magma mush' inside an active volcano

Ecuador volcano spews giant ash column

Guatemala volcano roars back to life

EPIDEMICS
Cow dung and old tyres inspire S.African township artists

Pro-Compaore politician arrested in Burkina over failed coup

Eutelsat and Facebook to partner on vsat initiative to get Africa online

Two Niger soldiers killed in 'Boko Haram ambush'

EPIDEMICS
Breakthrough for electrode implants in the brain

Researchers build a digital piece of brain

Foot fossils of human relative shows evolutionary 'messiness' of bipeds

Research reveals new clues about how humans become tool users









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.